Cash and cash equivalents of €5.7 million as of September 30, 2024Execution of clinical strategy as planned, with the GLORIA global Phase II study initiation expected in the first quarter of 2025 Lyon ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback